质子抑制剂的使用:对全球趋势和实践的系统审查
Lelwala Guruge Thushani Shanika1,2, Andrew Reynolds3, Sharon Pattison3
1New Zealand Pharmacovigilance Centre, University of Otago, 913, Dunedin, 9054, New Zealand.
European journal of clinical pharmacology
|July 7, 2023
概括
全球近四分之一的成年人使用质子抑制剂 (PPI). 这次审查强调了PPI的广泛使用,许多患者服用高剂量或长期使用,这表明需要更合理的处方.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 胃肠病学 胃肠病学
- 公共卫生 公共卫生
背景情况:
- 质子抑制剂 (PPI) 在全球范围内广泛用于抑制酸性.
- 虽然短期使用PPI是安全的,但长期使用PPI会带来新兴风险.
- 关于全球PPI使用模式的证据有限.
结论:
- 广泛使用PPI,特别是长期使用和高剂量使用,需要对处方实践进行审查.
- 临床医生应该定期评估PPI的必要性,并在适当时停止处方.
- 合理化PPI使用可以减轻潜在的健康危害,降低治疗成本.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
472
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
472
Peptic Ulcer Disease IV: Management
113
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
113
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
517
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
517
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
462
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
462
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
507
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
507
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
468
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
468


